3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
6
Completed
5
Not yet recruiting
3
Active not recruiting
2
Unknown
1
No longer available
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Lymphoma, Large B-Cell, Diffuse
7
Recurrence
2
Waldenstrom Macroglobulinemia
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, B-Cell
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Interventions
Cyclophosphamide
3
sargramostim
2
ibrutinib
2
Rituximab
2
Peripheral Blood Stem Cell Transplantation
2
Filgrastim
2
zanubrutinib
1
obinutuzumab
1
motesanib diphosphate
1
ledipasvir, sofosbuvir drug combination
1
ibritumomab tiuxetan
1
fludarabine phosphate
1
alethine
1
XELOX
1
Valproic Acid
1
Thalidomide
1
Radiotherapy
1
Psychiatric Rehabilitation
1
Pharmacogenomic Testing
1
Melphalan
1
Leukapheresis
1
Ketamine
1
Interferon-alpha
1
Indium
1
Ifosfamide
1
Gemcitabine
1
Etoposide
1
Dexamethasone
1
Cytarabine
1
Cisplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Waldenstrom Macroglobulinemia
×
zanubrutinib
×
Clear all
NCT05979948
2023-09-14
CZ-WM01
Shanghai Changzheng Hospital
Phase 2
Unknown
60 enrolled